ADRO Aduro Biotech, Inc.

10.20
+0.20  (2%)
Previous Close 10.00
Open 10.05
Price To book 3.05
Market Cap 713.11M
Shares 69,913,000
Volume 583,405
Short Ratio 21.23
Av. Daily Volume 394,011

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated 2Q 2017.
CRS-207 with anti-PD1
Gastric cancer
Phase 2b primary endpoint not met - May 2016
CRS-207 and GVAX Pancreas - ECLIPSE trial
Pancreatic cancer
Partial clinical hold announced October 24, 2016. Hold released November 21, 2016.
CRS-207 and GVAX Pancreas and nivolumab - STELLAR trial
Pancreatic cancer
Phase 1/2 dosing initiated March 2016.Partial clinical hold announced October 24, 2016. Hold released November 21, 2016.
Epacadostat and CRS-207 - SEASCAPE
Ovarian cancer
Phase 2 trial to be initiated 2Q 2017 with early data due 2H 2017.
CRS-207 with anti-PD1
Mesothelioma - cancer

Latest News

  1. Aduro Biotech, Merck Team on Cancer Drug Trial
  2. Aduro Biotech Announces Clinical Collaboration with Merck to Evaluate the Combination of Aduro’s CRS-207 with Merck’s KEYTRUDA® (Pembrolizumab) for the Treatment of Mesothelioma
  3. ETFs with exposure to Aduro BioTech, Inc. : May 5, 2017
  4. Aduro BioTech, Inc. :ADRO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 4, 2017
  5. Aduro Biotech reports 1Q loss
  6. Aduro Biotech Reports First Quarter 2017 Financial Results
  7. Aduro Biotech to Present at Two Investor Conferences in May
  8. Aduro Biotech Announces Management Promotions
  9. ETFs with exposure to Aduro BioTech, Inc. : April 5, 2017
  10. Why Is Aduro (ADRO) Down 3.6% Since the Last Earnings Report?
  11. Aduro Biotech, Inc. (Nasdaq: ADRO) to Ring The Nasdaq Stock Market Opening Bell
  12. Aduro BioTech, Inc. :ADRO-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017
  13. Aduro BioTech, Inc. :ADRO-US: Earnings Analysis: 2016 By the Numbers : March 16, 2017
  14. Aduro Biotech to Host Research and Development Day in New York
  15. Aduro Biotech Awarded East Bay Innovation Award for its Contributions in Life Sciences and the San Francisco East Bay Community
  16. Aduro Biotech Announces Upcoming Data Presentations at the 2017 American Association for Cancer Research Annual Meeting
  17. Aduro (ADRO) Loss Wider than Expected, Sales Miss in Q4
  18. Aduro Biotech Announces Upcoming Data Presentations at the Keystone Symposia on Cancer Immunology and Immunotherapy Conference
  19. Aduro Biotech Announces Fourth Quarter and Full Year 2016 Financial Results